Descovy (emtricitabine/tenofovir alafenamide) Letter of Medical Necessity
Descovy (FTC/TAF) PA for PrEP often requires step therapy through generic Truvada. Patient-specific renal or bone health concerns can justify Descovy selection.
FDA-Approved Indications
- ● HIV-1 treatment as part of a complete regimen
- ● HIV PrEP in adults and adolescents at risk (excluding individuals at risk via receptive vaginal sex)
Why Descovy Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Generic Truvada (TDF/FTC) preferred for PrEP
- 2. Renal/bone risk justification missing
- 3. Indication not specified
What to Include in a Descovy Letter of Medical Necessity
Document indication, HIV risk profile, renal function, BMD/osteoporosis risk, prior PrEP trial outcomes, and rationale for TAF over TDF.
Key clinical evidence to cite:
- ✓ DISCOVER trial for PrEP
- ✓ Multiple HIV treatment studies
Relevant guidelines:
- 📖 CDC PrEP Guidelines
- 📖 DHHS HIV Guidelines
Descovy Prior Authorization Criteria
Standard criteria across major US payers for Descovy. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Descovy
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Descovy Prior Authorization FAQ
Why was my Descovy prior authorization denied?
The most common denial reasons for Descovy are: Generic Truvada (TDF/FTC) preferred for PrEP; Renal/bone risk justification missing; Indication not specified.
What should a Descovy Letter of Medical Necessity include?
Document indication, HIV risk profile, renal function, BMD/osteoporosis risk, prior PrEP trial outcomes, and rationale for TAF over TDF.
Which payers cover Descovy?
Descovy is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, CVS Caremark, though formulary tier and prior authorization criteria vary.